INFLIXIMAB and ADALIMUMAB in Uveitic Macular Edema

Autor:	Phuc LeHoang, D. Saadoun, Bahram Bodaghi, Christine Fardeau, Raphael Lejoyeux, Eleonore Diwo, S Tezenas du Montcel, H. Vallet
Rok vydání:	2018
Předmět:	musculoskeletal diseases Adult Male medicine.medical_specialty Anti-Inflammatory Agents Visual Acuity Gastroenterology Macular Edema Uveitis 03 medical and health sciences 0302 clinical medicine Refractory Internal medicine medicine Adalimumab Immunology and Allergy Humans Fluorescein Angiography skin and connective tissue diseases Macular edema Retrospective Studies 030203 arthritis & rheumatology Retinal vasculitis business.industry Tumor Necrosis Factor-alpha Retrospective cohort study Middle Aged medicine.disease Infliximab Ophthalmology Treatment Outcome Ophthalmologic examination 030221 ophthalmology & optometry Female business Tomography Optical Coherence medicine.drug
Zdroj:	Ocular immunology and inflammation. 26(7)
ISSN:	1744-5078
Popis:	Purpose To compare the efficacy of infliximab and adalimumab in patients with refractory uveitis-related macular edema (ME). Methods A retrospective study was conducted in all patients with refractory uveitis-related ME treated with infliximab or adalimumab in Pitie-Salpetriere hospital between January 1, 2006 and January 1, 2016. All patients underwent a complete ophthalmologic examination, OCT and retinal angiography at baseline, and 6 (M6) and 24 months (M24) after treatment initiation. Main outcome was a decrease in central foveal thickness (CFT) on OCT. Results Twenty-five patients were included: 12 treated with adalimumab and 13 treated with infliximab. The median baseline CFT was 381 μm (Q1 = 254; Q3 = 470) in the adalimumab group and 469 μm (307; 539) in the infliximab group. At M6, 6/12 adalimumab-treated patients (50%) and 8/13 infliximab-treated patients (61%) were responders. The median CFT decrease from baseline was 61 μm (17-136) and 66 μm (-59-119) respectively at M6 and M24 in the adalimumab group versus 92 μm (9-165) and 52 μm (33-130) respectively at M6 and M24 in the infliximab group (all p > 0.05). Conclusion No significant difference in efficacy was observed between infliximab and adalimumab at M6 and M24.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::641428bed10dd873b75db124583dd015 https://pubmed.ncbi.nlm.nih.gov/30096013 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.